Targeting a key protein to treat acute myeloid leukemia
Selective targeting of TAF1 function in acute myeloid leukemia
This study is looking at new ways to treat acute myeloid leukemia (AML) by focusing on a protein called TAF1, with the hope of creating drugs that can safely target this protein and improve treatment for patients while causing fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-11037968 on NIH RePORTER |
What this research studies
This research focuses on developing new therapies for acute myeloid leukemia (AML) by targeting a protein called TAF1, which plays a crucial role in the disease's progression. The researchers are using innovative techniques to create drugs that can effectively degrade TAF1, potentially leading to better treatment outcomes for patients. By understanding how TAF1 functions in AML, they aim to design targeted therapies that minimize effects on normal blood cells, thereby reducing side effects. The study involves both laboratory experiments and the development of new drug compounds.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia, particularly those with specific genetic markers related to TAF1.
Not a fit: Patients with other types of leukemia or those who do not have the genetic markers associated with TAF1 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with acute myeloid leukemia.
How similar studies have performed: While targeting TAF1 is a relatively novel approach, similar strategies targeting other proteins in cancer have shown promising results in previous studies.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Schonbrunn, Ernst — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Schonbrunn, Ernst
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.